The Life Sciences Report
Three views on living and investing in the U.S. Commonwealth
Notable Quotes
"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >
"ATHX's MultiStem has the potential to completely change existing treatment paradigms." (4/2/14) Athersys Inc. - Jason Kolbert, Maxim Group More >
"BLU presented to our advisory board and came out as one of the favorites." (3/19/14) BELLUS Health Inc. - The Life Sciences Report Interview with Hugh Cleland More >
"Positive clinical data will make CTH's APL-130277 a very attractive asset for specialty pharma or large pharma." (3/19/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Stephen Ireland More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Valeant Pharmaceuticals International Inc.TICKER: VRX:NYSE; VRX:TSX
|